



**Fortis Healthcare Limited**  
Support Office:  
Tower A, Unitech Business Park,  
Block - F, South City 1, Sector - 41,  
Gurgaon, Haryana - 122001 (India)  
Tel : 0124 492 1021  
Fax : 0124 492 1041  
Ambulance : 105010  
E-mail : [secretarial@fortishealthcare.com](mailto:secretarial@fortishealthcare.com)  
Website : [www.fortishealthcare.com](http://www.fortishealthcare.com)

FHL/SEC/STEX/RR/2017-18

May 30, 2017

**The National Stock Exchange of India Ltd.**  
Corporate Communications Department  
"Exchange Plaza", 5<sup>th</sup> Floor,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai - 400051  
Scrip Symbol: FORTIS

**BSE Limited**  
Corporate Services Department  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001  
Scrip Code:532843

**Sub: Outcome of the Board Meeting**

Dear Sir(s),

This is to inform you that the Board of Directors of the Company at its meeting held today, *inter-alia*, considered and approved the Audited Consolidated and Standalone Financial Results of the Company for the quarter and year ended on March 31, 2017.

M/s. Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company have issued Auditors Report with an unmodified opinion on the Financial Statements.

The Board Meeting commenced at 1200 Noon and concluded at 1730 Hours.


This is for your information and records please.

Thanking you,

Yours faithfully,

**For Fortis Healthcare Limited**



**Rahul Ranjan**  
Company Secretary  
Membership No.: A17035



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

(₹ In lacs)



Particulars	Consolidated						Standalone								
	Quarter ended			Year ended			Quarter ended			Year ended					
	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-16	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	Audited
	Unaudited (Refer note 2)	Unaudited	Unaudited (Refer note 2)	Audited	Audited	Audited	Unaudited (Refer note 2)	Unaudited (Refer note 2)	Unaudited (Refer note 2)	Unaudited (Refer note 2)	Unaudited (Refer note 2)	Audited	Audited	Audited	Audited
1. Income from operations	112,343	113,338	107,018	457,371	419,889	15,199	15,403	15,766	15,403	64,512	61,159	64,512	18,469	18,469	18,469
2. Other income (including derivative gain, refer note 14)	3,607	5,893	1,844	16,600	15,350	4,091	7,600	4,231	7,600	16,920	16,920	16,920	16,920	16,920	16,920
<b>3. Total income (1+2)</b>	<b>115,950</b>	<b>119,231</b>	<b>108,862</b>	<b>473,971</b>	<b>435,239</b>	<b>19,290</b>	<b>23,003</b>	<b>19,997</b>	<b>23,003</b>	<b>81,432</b>	<b>79,628</b>	<b>81,432</b>	<b>79,628</b>	<b>79,628</b>	<b>79,628</b>
4. Expenses															
(a) Cost of material consumed	24,561	23,579	24,096	99,756	94,167	3,394	3,626	3,726	3,626	15,051	14,455	15,051	14,455	14,455	14,455
(b) Employee benefits expenses	23,327	22,722	22,014	90,891	82,435	4,566	4,611	4,686	4,611	19,015	18,151	19,015	18,151	18,151	18,151
(c) Finance costs	6,661	7,479	3,790	22,944	13,305	2,061	2,243	3,117	2,243	10,636	6,512	10,636	6,512	6,512	6,512
(d) Hospital service fee	9,248	10,146	14,902	50,508	59,257	3,310	3,322	3,377	3,322	13,604	13,247	13,604	13,247	13,247	13,247
(e) Professional charges to doctors	13,716	13,491	12,645	53,472	47,831	1,826	1,798	1,870	1,798	7,647	7,802	7,647	7,802	7,802	7,802
(f) Reversal of derivative gain (refer note 14)	-	-	-	-	-	-	-	5,636	-	5,636	-	5,636	-	-	-
(g) Net depreciation/ impairment & amortisation	6,301	5,994	7,213	22,218	22,510	750	826	653	826	2,662	2,542	2,662	2,542	2,542	2,542
(h) Other expenses	33,591	32,172	28,696	127,456	115,795	4,798	4,572	4,812	4,572	18,214	20,063	18,214	20,063	20,063	20,063
<b>Total expenses</b>	<b>117,405</b>	<b>115,583</b>	<b>113,356</b>	<b>467,245</b>	<b>435,300</b>	<b>20,705</b>	<b>20,998</b>	<b>27,877</b>	<b>20,998</b>	<b>92,465</b>	<b>82,772</b>	<b>92,465</b>	<b>82,772</b>	<b>82,772</b>	<b>82,772</b>
5. Net profit / (loss) from continuing operations before share in profit/ (loss) of associates and joint ventures (3-4)	(1,455)	3,648	(4,494)	6,726	(61)	(1,415)	2,005	(7,880)	2,005	(11,033)	(3,144)	(11,033)	(3,144)	(3,144)	(3,144)
6. Add : Share in profit /(loss) of associate companies and joint ventures (refer note 13)	410	43,764	1,711	48,606	7,247	-	-	-	-	-	-	-	-	-	-
<b>7. Net profit / (loss) before exceptional items and tax (5+6)</b>	<b>(1,045)</b>	<b>47,412</b>	<b>(2,783)</b>	<b>55,332</b>	<b>7,186</b>	<b>(1,415)</b>	<b>2,005</b>	<b>(7,880)</b>	<b>2,005</b>	<b>(11,033)</b>	<b>(3,144)</b>	<b>(11,033)</b>	<b>(3,144)</b>	<b>(3,144)</b>	<b>(3,144)</b>
8. Exceptional gain/ (loss) (refer note 9)	(77)	(180)	(6,763)	(164)	(4,014)	(90)	8	(180)	8	(373)	(1,822)	(373)	(1,822)	(1,822)	(1,822)
<b>9. Profit / (loss) before tax from continuing operations (7-8)</b>	<b>(1,122)</b>	<b>47,232</b>	<b>(9,546)</b>	<b>55,168</b>	<b>3,172</b>	<b>(1,505)</b>	<b>2,013</b>	<b>(8,060)</b>	<b>2,013</b>	<b>(11,406)</b>	<b>(4,966)</b>	<b>(11,406)</b>	<b>(4,966)</b>	<b>(4,966)</b>	<b>(4,966)</b>
10. Tax expense/ (credit)	2,630	1,903	(786)	7,240	(802)	(1,348)	1,116	(1,913)	1,116	(3,934)	(946)	(3,934)	(946)	(946)	(946)
<b>11. Net profit / (loss) for the period from continuing operations (9-10)</b>	<b>(3,752)</b>	<b>45,329</b>	<b>(8,760)</b>	<b>47,928</b>	<b>3,974</b>	<b>(157)</b>	<b>897</b>	<b>(6,147)</b>	<b>897</b>	<b>(7,472)</b>	<b>(4,020)</b>	<b>(7,472)</b>	<b>(4,020)</b>	<b>(4,020)</b>	<b>(4,020)</b>
12. Profit from discontinued operations before tax	-	-	-	-	232	-	-	-	-	-	-	-	-	-	-
13. Tax expense of discontinued operations	-	-	-	-	27	-	-	-	-	-	-	-	-	-	-



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

(₹ In lacs)

Particulars	Consolidated						Standalone			
	Quarter ended			Year ended			Quarter ended		Year ended	
	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	
14. Net profit / (loss) for the period from discontinuing operations (12-13)	-	-	-	-	205	-	-	-	-	-
15. Net profit / (loss) for the period (11+14)	(3,752)	45,329	(8,760)	47,928	4,179	(157)	(6,147)	897	(7,472)	(4,020)
16. Profit/ (loss) from continuing operations attributable to:										
Owners of the Company	(6,783)	44,192	(9,990)	42,166	1,639					
Non Controlling Interest	3,031	1,137	1,230	5,762	2,335					
17. Profit/ (loss) from discontinuing operations attributable to:										
Owners of the Company	-	-	-	-	203					
Non Controlling Interest	-	-	-	-	2					
18. Other Comprehensive Income/(loss) (including OCI relating to associates and joint venture (after tax)) ('OCI')	(470)	(1,984)	1,406	(2,734)	(5,074)	164	(55)	(57)	107	189
19. Total comprehensive Income/(Loss) (15+18)	(4,222)	43,345	(7,354)	45,194	(895)	7	(6,202)	840	(7,365)	(3,831)
20. Total comprehensive Income/(Loss) attributable to:										
Owners of the Company	(7,229)	42,208	(8,578)	39,456	(3,226)					
Non Controlling interest	3,007	1,137	1,224	5,738	2,331					
21. Paid-up equity share capital (Face Value ₹10 per Share)	51,773	48,156	46,313	51,773	46,313	51,773	48,156	46,313	51,773	46,313
22. Reserves				462,576	369,803				375,413	328,428
23. Earnings per equity share for continuing operations										
Basic earnings (loss) per share - In Rupees	(0.79)	9.49	(1.91)	9.19	0.53	(0.03)	(1.32)	0.19	(1.57)	(0.87)





**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

(₹ In lacs)

Particulars	Consolidated						Standalone			
	Quarter ended			Year ended			Quarter ended		Year ended	
	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	31-Mar-17	31-Mar-16	
Diluted earnings (loss) per share - In Rupees	(0.79)	8.85	(1.95)	9.19	0.30	(0.03)	(1.32)	0.19	(1.57)	(0.87)
<b>24. Earnings per equity share for discontinued operations</b>										
Basic earnings (loss) per share - In Rupees	-	-	-	-	0.04	-	-	-	-	-
Diluted earnings (loss) per share - In Rupees	-	-	-	-	0.04	-	-	-	-	-
<b>25. Earnings per equity share from continuing and discontinued operations</b>										
Basic earnings (loss) per share - In Rupees	(0.79)	9.49	(1.91)	9.19	0.57	(0.03)	(1.32)	0.19	(1.57)	(0.87)
Diluted earnings (loss) per share - In Rupees	(0.79)	8.85	(1.95)	9.19	0.35	(0.03)	(1.32)	0.19	(1.57)	(0.87)
<b>26. Earnings before depreciation and amortization expense, finance costs, exceptional items, tax expenses and share in profit / (loss) of associate companies and joint ventures (EBITDA) (refer note 18)</b>	11,507	17,121	6,509	51,888	35,754	1,396	(4,110)	5,074	2,265	5,910

**Notes to the results**

1. The above financial results for the quarter and year ended March 31, 2017 have been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their respective meetings held on May 29, 2017 and May 30, 2017.
2. The figures for the quarter ended March 31, 2017 and March 31, 2016 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2017 and March 31, 2016 respectively and the unaudited published year to date figures up to December 31, 2016 and December 31, 2015 respectively, being the end of the third quarter of the respective financial years, which were subjected to a limited review.
3. The Company adopted Indian Accounting Standards (Ind AS) with effect from April 1, 2016 and accordingly these financial results along with the comparatives have been prepared in accordance with the recognition and measurement principles stated therein, prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. The reconciliation of Net Profit/(Loss) and Equity between financial results for the quarter and year ended March 31, 2016, as previously reported (referred to as 'Previous GAAP') and Ind AS are summarised as below :




**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

a) Net Profit/(Loss) Reconciliation

( ₹ in lacs)

Sr. No.	Nature of Adjustment	Consolidated		Standalone	
		Quarter ended 31-Mar-16	Year ended 31-Mar-16	Quarter ended 31-Mar-16	Year ended 31-Mar-16
1	<b>Net profit before minority interest under Previous GAAP (A)</b>	<b>(8,553)</b>	<b>(355)</b>	<b>(1,400)</b>	<b>(7,351)</b>
	Borrowings & debt portion of compound instruments accounted based on effective interest rate	(67)	(170)	(46)	(140)
2	Financial assets accounted at fair value through profit and loss	(1,334)	402	3,743	3,735
3	Share based payments accounted based on fair value	(310)	(780)	(248)	(665)
4	Change in classification of associates/ subsidiaries and other consolidation adjustments	42	413	-	-
5	Deferred tax adjustments/ recognition	1,850	5,232	(1,216)	846
6	Actuarial (gain)/ loss on employee defined benefit plans recognised through other comprehensive income (OCI) (after tax)	34	4	57	(189)
7	Others	(422)	(567)	7	(256)
	Total adjustments (1+2+3+4+5+6+7) (B)	(207)	<b>4,534</b>	2,297	<b>3,331</b>
	<b>Net profit before OCI as per Ind AS (C = A+B)</b>	<b>(8,760)</b>	<b>4,179</b>	<b>897</b>	<b>(4,020)</b>
	Other Comprehensive Income (OCI) after tax (D)	1,406	(5,074)	(57)	189
	<b>Total Comprehensive Income as per Ind AS (C+D)</b>	<b>(7,354)</b>	<b>(895)</b>	<b>840</b>	<b>(3,831)</b>

Other comprehensive income includes re-measurement gains / losses on actuarial valuation of post-employment defined benefits and effect of foreign currency translation on consolidation.



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

b) Equity Reconciliation

Sr. No.	Nature of Adjustment	( ₹ in lacs)	
		Consolidated As at 31-Mar-16	Standalone As at 31-Mar-16
	<b>Total equity as per Previous GAAP (A)</b>	<b>481,039</b>	<b>360,827</b>
1	Fair value adjustment to financial asset	9,536	14,916
2	Equity portion of compound instrument	1,664	1,664
3	Borrowings & debt portion of compound instruments accounted based on effective interest rate	(1,240)	(1,357)
4	Change in classification of associates/ subsidiaries and other consolidation adjustments	(3,552)	-
5	Remeasurement of goodwill on acquisition on Non-controlling interest	(8,723)	-
6	Deferred tax adjustments/ recognition	5,376	(1,334)
7	Dividends not recognised as liability until declared under Ind AS	42	-
8	Others	1,139	25
	Total adjustments (1+2+3+4+5+6+7+8) (B)	4,242	13,914
	<b>Total equity as reported under Ind AS (A+B)</b>	<b>485,281</b>	<b>374,741</b>



4. Segment Reporting

**Business segments:**

The Group is primarily engaged in the business of healthcare services, which in the opinion of management is considered to be the only reportable business segment as per Ind AS 108 on 'Operating Segments' prescribed under Section 133 of the Companies Act, 2013. Healthcare services include various patient care services delivered through clinical establishment, medical services companies, pathology and radiology services etc.

**Geographical segments:**

The Group operates in the business segment explained above in two principal geographical areas, India and outside India. The geographical segments have been identified as secondary segment. The Group operates in two principal geographical segments, which contributes more than 10% of the Groups' revenue or segment assets. Outside India, Group now primarily operates in Dubai, Singapore and Mauritius.



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

*Income from operations – by geographical segments*

The following table shows the distribution of the Groups' consolidated revenues by geographical segment:

Region	Quarter ended			Year ended	
	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16
India	110,590	109,251	105,155	447,788	414,707
Outside India	1,753	4,087	1,863	9,583	5,182
<b>Total</b>	<b>112,343</b>	<b>113,338</b>	<b>107,018</b>	<b>457,371</b>	<b>419,889</b>

(₹ In lacs)


Carrying value of Assets and additions to tangible and intangible fixed assets- by location of assets

The following table shows the carrying amount of segment assets and additions to tangible and intangible fixed assets by geographical area in which the assets are located:

Region	Carrying amount of Segment assets		Additions to Fixed & Intangible assets	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
India	818,874	585,675	199,138	49,900
Outside India	152,827	138,231	162	212
<b>Total</b>	<b>971,701</b>	<b>723,906</b>	<b>199,300</b>	<b>50,112</b>


(₹ in lacs)

5. Other income includes interest income, foreign exchange fluctuation gain (net), profit on sale of assets (net), fair value adjustments, dividend on investments, forward cover premium amortization (net) and miscellaneous income, etc. whichever is relevant for the period.
6. In case of one of the subsidiaries ("Escorts Heart Institute and Research Centre Limited") ('EHIRCL'), that was formed after amalgamation of Escorts Heart Institute and Research Centre ('EHIRC'), Delhi Society with EHIRC, Chandigarh Society and thereafter registration of EHIRC, Chandigarh Society as a company.
  - a) Delhi Development Authority ('DDA') had terminated the lease deeds and allotment letters relating to land parcels on which a hospital of EHIRCL exists. Consequent to termination, DDA issued show cause notice and initiated eviction proceedings against EHIRCL. Both these matters are currently pending in various courts of law. Based on the external legal counsel opinions, Management is confident that EHIRCL will be able to suitably defend the termination order and eviction proceedings and accordingly considers that no adjustments are required to the financial results.



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

- b) Further, EHIRCL also has open tax demands of ₹ 10,213 lacs (after adjusting ₹ 12,756 lacs of an escrow account which was maintained out of sale consideration payable by the Company to the erstwhile promoters) for various assessment years. Further, as per the share purchase agreement, one third of any excess of these demands after adjusting the recovery from escrow account amounting to ₹ 3,404 lacs would be borne by the said erstwhile promoters and the rest by the Company, if any. During the year ended March 31, 2015, the Commissioner of Income Tax (Appeals) decided the case in favour of EHIRCL. Income Tax Department has filed an appeal before Income Tax Appellate Tribunal (ITAT), and the matter is currently pending at ITAT.
- c) In relation to the judgement of the Hon'ble High Court of Delhi relating to provision of free treatment/ beds to poor, Directorate of Health Services ('DHS'), Government of NCT of Delhi, appointed a Firm to calculate "unwarranted profits" arising to it due to non-compliance. During the year ended March 31, 2014, the Special Committee of DHS stated that before giving a hearing to the hospital, a formal intimation shall be given regarding the recoverable amount as per calculation of the appointed Firm, which as per their method of calculations amounts to ₹ 73,266 lacs for the period 1984-85 to 2011-12, seeking hospital's comments and inputs, if any. The company responded to said intimation explaining errors and objections to the calculations. During the previous year, EHIRCL received notice from DHS to appear for a formal and final hearing raising demand of recoverable amount to ₹ 50,336 lacs for the period till FY 2006 -2007 in terms of above referred judgement, against which the Company again responded explaining errors and objections to the calculations. During the quarter ended June 30, 2016, DHS issued a demand notice dated June 9, 2016 directing EHIRCL to deposit ₹ 50,336 lacs within one month. EHIRCL challenged the demand notice by way of a writ petition in Hon'ble High Court of Delhi which vide order dated August 1, 2016 has set aside the demand of ₹ 50,336 lacs which was raised vide notice dated June 9, 2016 and disposed of the petition of EHIRCL. DHS agreed to grant hearing to EHIRCL on the reply submitted to it. Hearings held before DHS but no order has been passed till date. Based on its internal assessment and advice from its external legal counsel on the basis of the documents available, management believes that it is in compliance of conditions of free treatment and free beds to the poor and does not anticipate liability after proper hearing with DHS.
7. In case of one of the subsidiaries ("Hiranandani Healthcare Private Limited") ("HHPL"):
- Navi Mumbai Municipal Corporation ("NMMC") has terminated the Hospital lease agreement with HHPL vide order dated 18 January, 2017 (Termination Order) for certain alleged contravention of the Hospital Lease agreement. NMMC has granted a period of one month to HHPL to hand over the possession of the hospital to NMMC and also directed HHPL not to admit any new patients. HHPL has filed Writ Petition before the Supreme Court of India challenging the Termination Order. The Writ Petition has been tagged with Special Leave Petition also filed by HHPL inter alia challenging the actions of State Government, City Industrial Development Corporation and NMMC which led to the passing of the said Termination Order. The Supreme Court of India in hearing held on 30 January, 2017 has ordered "Status Quo" which is continuing. Based on the external legal counsel opinion, management is confident that HHPL is in compliance of conditions of Hospital Lease Agreement and accordingly considers that no adjustment is required to the financial results.







**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

8. Statement of Assets and Liabilities :



Particulars	(₹ in lacs)			
	Consolidated		Standalone	
	As at 31-Mar-17	As at 31-Mar-16	As at 31-Mar-17	As at 31-Mar-16
<b>ASSETS</b>				
<b>Non-current assets</b>				
(a) Property, plant and equipment	297,399	142,553	14,182	12,657
(b) Capital work-in-progress	23,538	20,263	19,260	17,639
(c) Goodwill	232,587	210,645	3,293	3,293
(d) Other intangible assets	11,918	10,953	1,087	1,220
(e) Intangible assets under development	3,274	2,314	640	561
(f) Financial assets				
(i) Investments				
a) Investments in associates/Joint venture	148,631	88,302	5	5
b) Other investments	-	-	360,262	220,805
(ii) Trade receivables	1,093	1,962	-	471
(iii) Loans	1,359	6,169	69,797	134,469
(iv) Other financial assets	8,634	38,426	866	40,106
(g) Non current tax assets (Net)	38,329	32,754	5,645	9,510
(h) Deferred tax assets (Net)	23,314	22,500	6,700	2,823
(i) Other non-current assets	3,464	4,671	613	1,417
<b>Total non-current assets</b>	<b>793,540</b>	<b>581,512</b>	<b>482,350</b>	<b>444,976</b>
<b>Current assets</b>				
(a) Inventories	6,157	6,004	558	583
(b) Financial assets				
(i) Other investments	39,160	56,895	-	22,020
(ii) Trade receivables	47,294	44,406	7,554	10,234
(iii) Cash and cash equivalents	54,430	14,194	569	910
(iv) Bank balances other than (iii) above	219	2,529	-	-
(v) Loans	9,372	5,450	7,475	9,267
(vi) Other financial assets	11,106	7,791	16,547	14,912
(c) Other current assets	5,744	5,064	1,041	991
<b>Total current assets</b>	<b>173,482</b>	<b>142,333</b>	<b>33,744</b>	<b>58,917</b>
Assets classified as held for sale	4,679	61	-	-
<b>Total current assets</b>	<b>178,161</b>	<b>142,394</b>	<b>33,744</b>	<b>58,917</b>
<b>Total assets</b>	<b>971,701</b>	<b>723,906</b>	<b>516,094</b>	<b>503,893</b>



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

(₹ in lacs)

Particulars	Consolidated		Standalone	
	As at 31-Mar-17	As at 31-Mar-16	As at 31-Mar-17	As at 31-Mar-16
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
(a) Equity share capital	51,773	46,313	51,773	46,313
(b) Other equity	462,576	369,803	375,413	328,428
<b>Equity attributable to owners of the Company</b>	<b>514,349</b>	<b>416,116</b>	<b>427,186</b>	<b>374,741</b>
Non-controlling interests	116,728	69,165	-	-
<b>Total equity</b>	<b>631,077</b>	<b>485,281</b>	<b>427,186</b>	<b>374,741</b>
<b>Liabilities</b>				
<b>Non-current liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	127,870	86,686	18,311	63,755
(ii) Other financial liabilities	1,446	1,616	-	-
(b) Provisions	5,511	4,340	1,037	1,267
(c) Deferred tax liabilities (Net)	12,887	-	-	-
(d) Other non-current liabilities	261	216	-	-
<b>Total non-current liabilities</b>	<b>147,975</b>	<b>92,858</b>	<b>19,348</b>	<b>65,022</b>
<b>Current liabilities</b>				
(a) Financial liabilities				
(i) Borrowings	68,260	51,870	44,175	42,168
(ii) Trade payables	58,870	56,147	14,024	11,437
(iii) Other financial liabilities	40,808	22,138	8,383	7,933
(b) Provisions	6,100	4,399	1,296	1,237
(c) Current tax liabilities (Net)	1,581	1,201	-	-
(d) Other current liabilities	12,454	10,012	1,682	1,355
Liabilities directly associated with assets classified as held for sale	4,576	-	-	-
<b>Total current liabilities</b>	<b>192,649</b>	<b>145,767</b>	<b>69,560</b>	<b>64,130</b>
<b>Total liabilities</b>	<b>340,624</b>	<b>238,625</b>	<b>88,908</b>	<b>129,152</b>
<b>Total equity and liabilities</b>	<b>971,701</b>	<b>723,906</b>	<b>516,094</b>	<b>503,893</b>



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

9. Exceptional gain/ (loss) included in the above consolidated financial results include:


Particulars	Quarter ended				Year ended	
	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16	
	(₹ In lacs)					
a) Expenses on Composite Scheme of Arrangement and Amalgamation (Refer note 11)	(90)	(180)	-	(373)	-	
b) Gain/ (Loss) on impairment of investment and assets held in subsidiary companies	-	-	(6,263)	196	(6,263)	
c) Loss on closure/ disposal of certain operations by the Group	-	-	(563)	-	(4,745)	
d) Statutory Bonus (see note below)	13	-	63	13	(1,582)	
e) Gain on sale of investment in Radlink Asia Pte Limited ("Radlink") [Refer note 10 (a)]	-	-	-	-	7,695	
f) Gain on sale of investment in Fortis Healthcare Singapore Pte Limited ("FHS") [Refer note 10 (b)]	-	-	-	-	881	
<b>Net exceptional gain/ (loss)</b>	<b>(77)</b>	<b>(180)</b>	<b>(6,763)</b>	<b>(164)</b>	<b>(4,014)</b>	

Note: Statutory bonus considered as an exceptional item represents the amounts (accrued)/ reversed towards incremental bonus payable to existing and deemed employees by the Group for the period from April 1, 2014 to December 31, 2015 due to enactment of The Payment of Bonus (Amendment) Act, 2015 with retrospective effect from April 1, 2014.

10. a) Discontinued operations relating to Radlink-Asia Pte Limited, Singapore ("Radlink")

During the year ended March 31, 2015, Fortis Healthcare International Pte Limited (FH IPL), a wholly owned subsidiary of the Company announced its decision to divest its 100% shareholding in Radlink.

The transaction was completed on May 12, 2015 post approvals by the shareholders of Radlink and other regulatory authorities. The investment was sold to Fullerton Healthcare Group Pte. Limited for a consideration of SGD 111 million. Accordingly, assets and liabilities of Radlink do not form part of the consolidated assets and liabilities of the Company w.e.f. May 12, 2015. Such deconsolidation resulted in a net gain of ₹ 7,695 lacs and is included as an exceptional item in the year ended March 31, 2016.



**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**

The income and expenses in respect of the activities attributable to above discontinued operations included in the consolidated financial results are as follows:

Particulars	Quarter ended			Year ended	
	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16
Total income	-	-	-	-	1,062
Total expenses	-	-	-	-	830
<b>Profit before tax</b>	-	-	-	-	<b>232</b>
Tax expenses	-	-	-	-	27
<b>Profit after tax</b>	-	-	-	-	<b>205</b>

b) Discontinued operations relating to Fortis Healthcare Singapore Pte Limited ('FHS')

During the year ended March 31, 2015, Fortis Healthcare International Pte Limited (FH IPL), a wholly owned subsidiary of the Company announced its decision to divest 100% shareholding in FHS which holds and operates Fortis Surgical Hospital to Concord Medical Services (International) Pte Limited for SGD 55 million.

The transaction was concluded on April 7, 2015. Accordingly, assets and liabilities of FHS do not form part of the consolidated assets and liabilities of the Company w.e.f. April 7, 2015. Such deconsolidation resulted in a net gain of ₹ 881 lacs and is included as an exceptional item in the year ended March 31, 2016.

11. The Board of Directors of the Company at its meeting held on August 19, 2016 approved the proposal to demerge its diagnostic business, including that housed in its majority owned subsidiary SRL Limited ("SRL") into another majority owned subsidiary, Fortis Malar Hospitals Limited ("Fortis Malar") pursuant to a composite scheme of arrangement and amalgamation. The composite scheme also provides for the sale of its hospital business by Fortis Malar to the Company by way of a slump sale. The demerger shall be followed by SRL being merged with Fortis Malar as an integral part of the same composite scheme. On transfer of the diagnostic business to Fortis Malar and Fortis Malar issuing its equity shares to the shareholders of the Company, the diagnostic business (including SRL) will be demerged from the Company. The appointed date for the slump sale, demerger and merger under the composite scheme is January 1, 2017. The composite scheme of arrangement and amalgamation is subject to various judicial/regulatory and other required approvals and is therefore not considered as highly probable transaction. Pending such approvals, no effect of the proposed Scheme has been given in the Financial Results.

12. During the quarter ended December 31, 2016, the Company completed acquisition of Control in Fortis Hospital Limited (FHTL) by way of acquiring 51% economic interest over equity through purchase of the compulsorily convertible debentures (CCDs) from Fortis Global Healthcare Infrastructure Pte Ltd (FGHIPL) and amendment to the Shareholders Agreement with Fortis Health Management Limited (FHML), FGHIPL and FHML are subsidiaries of RHT Health Trust (RHT) which is an associate of the Group. Subsequent to the acquisition of 51% economic interest in FHTL, the Company has obtained Control over FHTL and the consolidated financial results for the year ended March 31, 2017 includes financial results of FHTL for the post acquisition period. As per requirement of Ind AS 103 "Business Combination", the Group has recorded goodwill on consolidation amounting to ₹ 23,376 lacs and fair value of net assets acquired amounting to ₹ 160,494 lacs as at the acquisition date.




**FORTIS HEALTHCARE LIMITED**  
**STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS**


13. Share in profit/ (loss) of associate companies and joint ventures for the quarter ended December 31, 2016 includes the Group's share of profit (in full) of around ₹ 42,117 lacs on gain recognized by its associate (RHT) arising from the disposal of FHTL business to FHL and consequent fair valuation of RHT's residual interest in FHTL under Ind AS 110. The same has been accounted for in full by the Group under Ind AS 28 considering it to be a disposal of a business by RHT, and a business acquisition for the Group accounted under Ind AS 103.
14. On completion of FHTL acquisition, the Company has reversed the derivative asset of ₹ 5,636 lacs in the previous quarter ended December 31, 2016 and year ended March 31, 2017, which was earlier recognized in the standalone financial results of the Company prepared under Ind AS in the quarter and year ended March 31, 2016 and year ended 31 March, 2015.
15. During the previous quarter ended December 31, 2016, the Company allotted 18,070,650 equity shares to Standard Chartered (Mauritius) III Limited against USD 30 Million Foreign Currency Convertible Bonds (FCCB), on exercise of conversion option as per Offering Circular.
16. During the current quarter ended March 31, 2017, the Company allotted 35,690,887 equity shares to International Finance Corporation against USD 55 Million FCCB, on exercise of conversion option as per FCCB Subscription Agreement.
17. During the previous year ended March 31, 2016, as per the agreed issue terms, the Company redeemed on due date the outstanding USD 100 million 5% FCCB listed on the Luxembourg stock exchange.
18. The Company has presented Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) additionally in the financial results. In its measurement, the Group includes other income, but does not include depreciation and amortization expense, finance costs, exceptional items, tax expenses and share in profit/(loss) of associates and joint ventures.
19. The previous year/quarters' figures have been regrouped/ reclassified wherever necessary to correspond with the current year / quarters' classification/ disclosure. The consolidated financial results include financial results of FHTL from the acquisition date, hence figures are not comparable with the previous periods.

Date: May 30, 2017  
Place: Gurgaon

For and on behalf of the Board of Directors



**Malvinder Mohan Singh**  
Executive Chairman



## INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF FORTIS HEALTHCARE LIMITED

1. We have audited the accompanying Statement of Standalone Financial Results of **FORTIS HEALTHCARE LIMITED** ("the Company"), for the year ended 31 March, 2017 included in the accompanying Statement of Standalone and Consolidated Financial Results ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Standalone Financial Results included in the Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone Ind AS financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Standalone Financial Results included in the Statement based on our audit of such standalone financial statements.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Standalone Financial Results included in the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Standalone Financial Results included in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Standalone Financial Results included in the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Standalone Financial Results included in the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Standalone Financial Results included in the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results included in the Statement:
  - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
  - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net loss and Total comprehensive loss and other financial information of the Company for the year ended 31 March, 2017.



**Deloitte  
Haskins & Sells LLP**

4. The Standalone Financial Results included in the Statement includes the results for the Quarter ended 31 March, 2017 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

Gurugram, 30 May, 2017  
RT/JB/2017



  
**RASHIM TANDON**  
Partner  
(Membership No. 095540)

## INDEPENDENT AUDITORS' REPORT TO THE BOARD OF DIRECTORS OF FORTIS HEALTHCARE LIMITED

1. We have audited the accompanying Statement of Consolidated Financial Results of **FORTIS HEALTHCARE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the profit/(loss) of its joint ventures and associates for the year ended 31 March, 2017 included in the accompanying Statement of Standalone and Consolidated Financial Results ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Consolidated Financial Results included in the Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Consolidated Financial Results included in the Statement based on our audit of such consolidated financial statements.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Consolidated Financial Results included in the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Consolidated Financial Results included in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Consolidated Financial Results included in the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Parent's preparation and fair presentation of the Consolidated Financial Results included in the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Parent's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Consolidated Financial Results included in the Statement.

We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements and the other financial statements of subsidiaries, associates and joint ventures referred to in paragraph 7 below, the consolidated financial results included in the Statement:





- A. includes the results of the following entities:
- a. Fortis Healthcare Limited (the Parent Company)
  - b. Fortis Hospitals Limited ("FHsL") (wholly owned subsidiary of the Parent Company) and results of its subsidiaries and joint ventures:
    - i. Birdie & Birdie Realtors Private Limited (wholly owned subsidiary of FHsL)
    - ii. Fortis C-Doc Healthcare Limited (joint venture of FHsL)
    - iii. Fortis Health Management (East) Limited (wholly owned subsidiary of FHsL)
    - iv. Fortis Cancer Care Limited ("FCCL") (wholly owned subsidiary of FHsL) and the results of its subsidiary Lalitha Healthcare Private Limited
    - v. Fortis Cauvery (joint venture of FCCL)
    - vi. Fortis Malar Hospitals Limited (subsidiary of FHsL) and the results of its wholly owned subsidiary Malar Stars Medicare Limited.
    - vii. Fortis Emergency Services Limited (subsidiary of FHsL)
    - viii. Stellant Capital Advisory Services Private Limited (wholly owned subsidiary of FHsL) and the results of its wholly owned subsidiary Religare Health Trust Trustee Manager Pte Limited.
    - ix. Fortis Global Healthcare (Mauritius) Limited (wholly owned subsidiary of FHsL w.e.f 4 October, 2016)
  - c. Escorts Heart Institute and Research Centre Limited ("EHIRCL") (wholly owned subsidiary of the Parent Company) and results of its subsidiaries and associate:
    - i. Fortis Health Staff Limited (subsidiary of EHIRCL)
    - ii. Fortis Asia Healthcare Pte. Limited (wholly owned subsidiary of EHIRCL) and the results of its wholly owned subsidiary Fortis Healthcare International Pte. Limited ("FHIPL")
    - iii. Radlink Asia Pte. Limited (wholly owned subsidiary of FHIPL) and the results of its subsidiaries and associates up to 12 May, 2015
    - iv. Fortis Healthcare Singapore Pte. Limited (wholly owned subsidiary of FHIPL) up to 05 April, 2015
    - v. Lanka Hospitals Corporation Plc (associate of FHIPL)
    - vi. Fortis Healthcare Middle East LLC (subsidiary of FHIPL)
    - vii. Mena Healthcare Investment Company Limited (subsidiary of FHIPL) and the results of its wholly owned subsidiary Medical Management Company Limited
    - viii. SRL Diagnostics FZ-LLC (wholly owned subsidiary of FHIPL) up to 07 July, 2016
  - d. SRL Limited ("SRL") (subsidiary of the Parent Company) and the results of its subsidiaries and joint venture entities :
    - i. SRL Diagnostics Private Limited (wholly owned subsidiary of SRL)
    - ii. SRL Reach Limited (wholly owned subsidiary of SRL)
    - iii. DDRC SRL Diagnostics Services Private Limited (joint venture of SRL)
    - iv. Super Religare Reference Laboratories (Nepal) Private Limited (joint venture of SRL)
    - v. SRL Diagnostics FZ-LLC (wholly owned subsidiary of SRL) with effect from 07 July, 2016
  - e. Hiranandani Healthcare Private Limited (subsidiary of the Parent Company)
  - f. Fortis Healthcare International Limited ("FHIL") (wholly owned subsidiary of the Parent Company) and results of its subsidiaries and associate:
    - i. Fortis Global Healthcare (Mauritius) Limited (wholly owned subsidiary of FHIL up to 3 October, 2016)
    - ii. Fortis Medicare International Limited (associate of FHIL)



- iii. RHT Health Trust (previously known as Religare Health Trust) and its subsidiaries (associate of FHIL)
  - iv. Medical and Surgical Centre Limited (associate of FHIL)
  - g. Fortis La Femme Limited (wholly owned subsidiary of the Parent Company)
  - h. Fortis Hospotel Limited (subsidiary of the Parent Company) with effect from 13 October, 2016.
- B. is presented in accordance with the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- C. gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit, Total comprehensive income and other financial information of the Group for the year ended 31 March, 2017.
4. We draw attention to notes 6(a), 6(b) and 6(c) to the Statement, regarding matters relating to outcome of income tax assessments, arbitrations with regard to termination of certain land leases allotted by Delhi Development Authority (DDA), and matter related to non-compliance with the order of the Honorable High Court of Delhi in relation to provision of free treatment/beds to poor against one of the subsidiaries ("Escorts Heart Institute and Research Centre Limited"). Based on the advice given by external legal counsel, no provision/adjustment has been considered necessary by the Management in this regard in the Consolidated Financial Results included in the Statement. Our opinion is not qualified in respect of this matter.
5. We draw attention to note 7 to the statement, regarding matter relating to termination of Hospital lease agreement by Navi Mumbai Municipal Corporation ('NMMC') vide order dated 18 January, 2017. Based on the advice given by external legal counsel, no provision/adjustment has been considered necessary by the Management in this regard in the Consolidated Financial Results included in the Statement. Our opinion is not qualified in respect of this matter.
6. We did not audit the financial statements of 4 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 21,219 lacs as at 31 March, 2017, total revenues of Rs. 1,734 lacs, total net loss after tax of Rs. 1,916 lacs and total comprehensive loss of Rs. 1,924 lacs for the year ended on that date, as considered in the consolidated financial results. The consolidated financial results also include the Group's share of net profit of Rs. 569 lacs and Total comprehensive income of Rs. 563 lacs for the year ended 31 March, 2017, as considered in the consolidated financial results, in respect of 1 joint venture, whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the Consolidated Financial Results included in the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint venture, is based solely on the reports of the other auditors.

We did not audit financial statements of 3 overseas associates and 1 overseas joint venture included in the consolidated results whose financial statements, prepared under Singapore Financial Reporting Standards "SFRS" and Nepal Accounting Standard "NAS" respectively, reflect Group's share of net profit of Rs. 60,696 lacs and Total comprehensive income of Rs. 61,316 lacs for the year ended 31 March, 2017, as considered in the consolidated financial results. The financial statements of the associates prepared in accordance with SFRS and joint venture prepared in accordance with NAS have been audited by other auditors who have submitted their conclusions, prepared under generally accepted auditing standards of their respective countries. The Management of the Parent has converted these financial statements



of the joint venture and associates to Ind AS, for the purpose of the preparation of the Consolidated Financial Results included in the Statement. Our opinion on the consolidated financial results included in the Statement, in so far it relates to amount and disclosures included in respect of the joint venture and associates, is based solely on the report of other auditors and our audit of the conversion process followed by the Management.

Our opinion on the Consolidated Financial Results included in the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of other auditors.

7. The consolidated financial results included in the Statement includes the unaudited financial statements of 8 subsidiaries, whose financial statements reflect total assets of Rs. 93,450 lacs as at 31 March, 2017, total revenue of Rs. 6,446 lacs, total net profit after tax of Rs. 516 lacs and Total Comprehensive income of Rs. 455 lacs for the year ended 31 March, 2017, as considered in the consolidated financial results. The consolidated financial results also includes the Group's share of profit after tax of Rs. 1,781 lacs and total Comprehensive Income of Rs. 1,781 lacs for the year ended 31 March, 2017, as considered in the consolidated financial results, in respect of 3 associates and 1 joint venture, whose financial statements have not been audited by us. These financial statements are unaudited and have been furnished to us by the Management and our opinion on this Consolidated Financial Results included in the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint venture and associates, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management, these financial statements are not material to the Group.

Our opinion on the Consolidated Financial Results included in the Statement is not modified in respect of the above matters with respect to our reliance on the financial statements certified by the Management.

8. The Consolidated Financial Results included in the Statement includes the results for the Quarter ended 31 March, 2017 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
9. The comparative financial information for the quarter and year ended March 31, 2016 in respect of 4 subsidiaries, 2 joint ventures and 3 associates included in this Consolidated Financial Results included in the Statement prepared in accordance with the Ind AS have been audited by other auditors and have been relied upon by us.

Our report is not qualified in respect of these matters.

For **DELOITTE HASKINS & SELLS LLP**  
Chartered Accountants  
(Firm's Registration No. 117366 W/W-100018)



  
**RASHIM TANDON**  
Partner  
(Membership No. 095540)

Gurugram, 30 May, 2017  
RT/JB/2017



## **PRESS RELEASE**

**FORTIS CONSOLIDATED REVENUES FOR FY17 AT RS 4,574 CR, UP 8.7%  
OPERATING EBITDA GROWS A ROBUST 75% TO RS 362 CR**

**HOSPITAL BUSINESS REVENUES FOR FY17 AT RS 3,712 CR, UP 8.3%  
OPERATING EBITDA INCREASES 3.6x TO RS 173 CR**

**SRL NET REVENUES FOR FY17 AT RS 795 CR, UP 10.6%  
OPERATING EBITDA AT RS 175 CR, 21.9% MARGINS**

**CONSOLIDATED REVENUES FOR Q4FY17 AT RS 1,123 CR, UP 5%  
OPERATING EBITDA UP 79% AT RS 84 CR**

**HOSPITAL BUSINESS REVENUES FOR Q4 AT RS 913 CR, UP 5%; OPERATING EBITDA UP 2.8x TO RS 46 CR  
SRL NET REVENUES AT RS 203 CR, UP 12.3%; OPERATING EBITDA AT RS 40 CR, 19.9% MARGINS**

**Gurgaon, May 30, 2017:** Fortis Healthcare Ltd. (Fortis), India's leading healthcare delivery Company, today, announced its consolidated results for the quarter and year ended March 31, 2017 (Q4FY17 and FY17).

### **Consolidated Business - Key Financial Highlights for the year (FY17)**

- Consolidated Revenues at Rs 4,574 Cr, up 8.7%. This is despite the impact of demonetization witnessed in H2FY17. Revenue growth in H1FY 17 (versus the corr. previous period) was at 9.7%, while in H2FY17 revenue growth stood at 7.6% largely as a result of demonetization.
- Consolidated Operating EBITDAC (EBITDA before net business trust costs) was at Rs 734 Cr, +10.5%, representing a margin of 16.1% versus 15.8% in the previous year. EBITDAC margins in H1FY 17 were at 17.2%, while in H2FY17 EBITDAC margins were at 14.8% largely as a result of demonetization.
- Consolidated Operating EBITDA was at Rs 362 Cr, up 75%, representing a margin of 7.9% versus a margin of 4.9% in the previous year.
- PBT before exceptional and foreign exchange gain/(loss) witnessed significant improvement at Rs 76.6 Cr versus Rs (52.5) Cr in the previous year
- PAT after Minority Interest and Share in Associates ( PATMI) was at Rs 426.1 Cr versus Rs 27.7 Cr in the previous year. PATMI includes a one-time gain in Share in Associates. This is the Company's share in the profits of RHT which includes the exceptional gain arising from the FHTL transaction recorded in Q3FY17.

- FY17 revenues for the India hospital business were at Rs 3,712 Cr, up 8.3%. Operating EBITDAC was at Rs 545 Cr, a growth of 7.9%. The EBITDAC for the India hospital business represents a margin of 14.7%, similar to previous year margins.
- Key operational parameters in the Company's hospital business continued to see a healthy uptrend. ARPOB (Average Revenue per Occupied Bed) grew to Rs 1.45 Cr compared to Rs 1.37 Cr in FY16, an increase of 6%. ALOS (Average length of stay) was at 3.56 days similar to previous year, while Occupancy improved to 75% versus 72% in FY16 respectively.
- FMRI, the Company's flagship facility recorded revenues of Rs 479 Cr in FY17, a healthy growth of 16% over the previous year. The flagship facility has become the highest ARPOB generating hospital in the Company's network of multi-specialty hospitals. The ARPOB at FMRI stood at Rs 2.58 Cr in FY17 (FY16: Rs 2.50 Cr). The hospital continues to record a strong improvement in operating profitability.
- Revenue at the Fortis Escorts facility, continued to ramp up. It recorded a revenue of Rs 402 Cr in FY17, an increase of 17% over the corresponding previous period and also continued to witness a steady improvement in its operating profitability.
- The India diagnostics business recorded revenues (net of inter company elimination) of Rs 795 Cr, up 10.6%. The operating profitability of the diagnostics business .i.e. EBITDA was at Rs 174.6 Cr, similar to the previous year. EBITDA margins stood at 21.9% against 24.3% in FY16.

\*EBITDAC refers to EBITDA before net business trust costs

#### **Consolidated Business - Key Financial Highlights for the quarter (Q4FY17)**

- Consolidated Revenues were at Rs 1,123 Cr versus Rs 1,070 Cr in the corresponding previous quarter, up 5%.
- Consolidated Operating EBITDAC (EBITDA before net business trust costs) was at Rs 148 Cr, representing a 13.2% margin, comparable to the 14.9% margin in the corresponding previous quarter.
- Consolidated Operating EBITDA at Rs 84 Cr, up 79% and representing a margin of 7.5% versus a margin of 4.4% in the corresponding previous quarter.
- PBT before exceptional and foreign exchange gain / (loss) witnessed significant improvement at Rs 17 Cr versus Rs (29) Cr in the corresponding quarter.
- PAT after Minority Interest and Share in Associates (PATMI) was at Rs (63.8) Cr versus Rs (90.7) Cr in the previous quarter.
- India hospital business revenues were at Rs 913 Cr versus Rs 871 Cr in Q4FY16. Operating EBITDAC in the quarter stood at Rs 110 Cr, representing a margin of 12.0%

versus 14.8% in the corresponding previous quarter. This compares to 14.3% in the trailing quarter.

- ARPOB (Average Revenue per Occupied Bed) in the quarter stood at Rs 1.50 Cr as compared to Rs 1.43 Cr in Q4FY16, a growth of 5%. ALOS (Average length of stay) was at 3.50 days versus 3.59 days in the previous corresponding quarter, while Occupancy stood at 70% versus 71% in Q4 FY16.
- The India diagnostics business recorded net revenues of Rs 203 Cr compared to Rs 181 Cr in Q4FY16, up 12.3%. The operating EBITDA was at Rs 40 Cr, representing an EBITDA margin of 19.9% compared to 22.6% in Q4FY16.

**Commenting on the results, Mr Bhavdeep Singh, CEO, Fortis Healthcare Ltd, said,** "For Fortis Healthcare, our driving force continues to be the vision of creating a world-class integrated healthcare delivery system focusing on clinical excellence, superior patient care and services. We have made substantial headway, in both these critical areas despite the impact of demonetization with our consolidated FY17 revenues up by 8.7%, our hospital business revenues up by 8.3%. Our diagnostic business revenues are also up by 10.6%. Overall, the key operational parameters in the company's hospital business continue to see a healthy uptrend. In the coming quarters, we will drive additional substantive gains as we further accelerate our efforts across all focus areas."

#### **Other Business Highlights – FY17**

- The Company in August 2016 announced the demerger of its diagnostics business and has since received a number of regulatory clearances as required. It filed a Composite Scheme of Arrangement and Amalgamation (demerger of diagnostics business) with the National Company Law Tribunal (NCLT), Chandigarh and has subsequently got approval from the all shareholders and creditors of Fortis Healthcare, SRL Limited and Fortis Malar. The next hearing by NCLT is scheduled for June end.
- In October 2016, the Company completed the acquisition of 51% economic interest in Fortis Hospotel Limited (FHTL) from RHT; witnessing a significant reduction in net BT costs – down 19% during the year. Since the deal was completed in October, the full impact of the reduction in the net BT costs would be significantly higher in FY18, further improving the Company's operating EBITDA.
- The Company during the year also issued shares in lieu of the conversion notice received by it from the FCCB holders for its USD 85 Mn equivalent bonds .i.e USD 30 Mn bonds listed on the SGX and USD 55 Mn bonds held by International Finance Corporation (IFC). The resulting capital post this conversion stands at approx. 51.7 Crore equity shares (excluding outstanding ESOPs). Post the above conversions, there are no further outstanding FCCBs / other convertible instruments.
- The Company continued to maintain a healthy Balance Sheet with a net debt to equity ratio of 0.20 times. Net debt stood at Rs 1281 Cr as on 31st March 2017. This compares

to a net debt of 0.16 times in the previous financial year and a net debt to equity ratio of 0.30 times as on December 31, 2016.

### **Key Highlights FY 17 - Hospital Business**

- In FY17, the top 10 facilities contributed approx. 77% of the hospital business revenue versus 76% in the previous year. Most facilities, including the larger ones at FMRI, Mohali, FEHI, Mulund, Noida, Shalimar Bagh, Anandpur and Ludhiana continued to exhibit growth momentum both in terms of revenues and operating margins.
- The contribution of International sales to the overall revenue of the Hospital business stood at 10.6% (Rs 395 Cr), a growth of 10% over the previous year. The retail business witnessed significant traction which was driven by a heightened level of on-ground activities, medical and surgical camps. The Company further strengthened these initiatives with the opening of 4 new Information Centres in FY17 in the Middle East and Myanmar.
- The Company continued to see healthy growth in the procedures performed across its facilities. Joint replacement surgeries (Knee and Hip) witnessed a strong growth of 28% with 10335 surgeries being performed during the year across the network. Transplant surgeries (Liver and Kidney) also witnessed a robust growth of 19%. The company also successfully performed close to 100 heart transplants during the year.
- In order to further strengthen its clinical programs and have the best available talent for treating its patients, the Company during FY17 witnessed the joining of a number of senior consultants in the urology, nephrology and orthopaedics specialties. These eminent doctors have brought on board their immense knowledge and vast experience thus enabling the Company to gain a sharper focus on enhancing patient care and clinical outcomes.
- As a part of its focus on growth through the O&M model, the Company during the year began operations in Rajasthan and Bangladesh. It also further strengthened its presence in Mauritius by taking over the operations and management of an existing hospital; adding to the existing hospital that it has been successfully managing for the past many years. The Company's philosophy under the O&M model works on minimum guarantee basis with nil investments; in return for providing its robust systems and processes, high calibre clinical and administrative acumen and a well-established 'Fortis' Brand name.
- In Q4FY17, the Company introduced and expanded its clinical programs and service offerings in several facilities in its network. These included :
  - A state-of-the-art Bone Marrow Transplant (BMT) unit inaugurated at FMRI. The 14-bed BMT ICU has 12 beds for adults and 2 paediatric beds.
  - To address the growing need for liver transplants and the treatment of liver related diseases, Fortis Hospital, Bannerghatta Road, launched a dedicated Centre for Hepatobiliary Sciences and Liver Transplant.
  - As part of International Women's Day, Fortis Malar Hospital, Chennai launched an All Women's Clinic. The multi-speciality clinic aims at providing a one-stop solution for women and is run by an all women team of clinicians and staff.

- After publishing FEHI's Cardiac Clinical outcomes data and Fortis Vasant Kunj's Kidney Transplant (1 year Survival) clinical outcomes data, five other Fortis hospitals joined this initiative. Fortis Mohali, Fortis Mulund, Fortis BG Road, Fortis CG Road and FMRI published cardiac clinical outcome data for CABG and PTCA procedures.

### **Key Highlights FY 17 - Diagnostics Business**

- The lab medicine i.e. the pathology business contributed 86% to total revenues and grew 9% over the previous year. The contribution of the imaging business to total revenues declined to 6.9% from 8.2% in the corresponding previous period, mainly due to network rationalization. Clinical Trials, Wellness and the International segment contributed 7% to the overall revenues of the Diagnostics business.
- SRL performed over 15.3 million accessions during the year, a 5.5% growth over last year. Through these accessions it undertook 35 million tests, up 7% as compared to 32.7 million tests in FY16. For the quarter, 3.8 million accessions were performed, a 5.6% growth over the corresponding quarter.
- The business continued to have a well -diversified geographical mix with no over dependence on any region, allowing it to optimally capitalize on its pan India network. The business witnessed 31% revenues from the north, 27% from the west, 19% from the south, 20% from East and Central India and 3% from International for the period ended March 31, 2017.
- SRL continued to grow its laboratory and collection centre network; adding 13 new laboratories and 31 collection centers while rationalising its portfolio with the closure of 4 laboratories and 34 collection centers in the quarter.
- As of March 31, 2017, SRL had a network of 356 labs and approx. 5245 collection points.

### **Clinical Excellence - Q4FY17**

- A team led by Dr K. R. Balakrishnan, Director – Cardiac Sciences and Dr Suresh Rao, Head of Cardiac Anaesthesia & Critical Care, performed a lifesaving heart transplant on a 78-year-old patient, making him possibly the oldest person to receive a heart transplant in the country.
- On January 19, 2017, Mumbai city witnessed its 40th Heart Transplant at Fortis Hospital, Mulund. The donor's heart was harvested at Fortis S.L. Raheja Hospital, Mahim and was transported to Fortis Mulund, covering a distance of 23 kms in 17 mins.
- A team led by Dr Vivek Vij, Director – Liver Transplant, Fortis Memorial Research Institute, Gurgaon, conducted a novel surgery to save the life of a 21-year-old Iraqi woman. The patient suffered from Budd Chiari Syndrome, a rare genetic disorder that causes blood clots in liver vessels.



- A team led by Dr Randeep Wadhawan, Director, Minimal Access Surgery, Bariatric & Gastrointestinal Surgery at Fortis Flt Lt Rajan Dhall Hospital, Vasant Kunj, New Delhi created history by removing the world's largest adrenal tumour, weighing 11.5 kgs, from a 55-year-old patient's stomach.
- A team of doctors at Fortis Hospital, Shalimar Bagh, New Delhi performed a meticulous two-hour laparoscopic procedure to remove 838 stones from the gall bladder of a patient. This is reportedly the highest number of gallstones ever extracted from a patient in India.
- A multi-speciality team of doctors at Fortis Hospital, Bannerghatta Road, Bengaluru, successfully treated a 2-month-old Iraqi baby suffering from a rare congenital condition wherein the urinary bladder is exposed and the urinary tract organs are malformed.
- A team of doctors at Fortis Hospital & Kidney Institute, Kolkata successfully performed a minimally invasive surgery to remove a 3 cm kidney stone in a 4-year-old boy from Lucknow.
- Dr Rama Joshi, Director - Gynae Oncology, FMRI, Gurgaon, became the first Gynae Onco Surgeon in Northern India to complete 50 robotic surgeries in record time using the Da Vinci Robot. Dr Joshi performed these surgeries on patients ranging from 9 years to 81 years in age.

#### **Awards & Accolades - Q4 FY17**

- Fortis Hospital, Bannerghatta Road, Bengaluru won a Gold at the Asian Hospital Management Awards (AHMA) for its 'Mission AAA' (Avoid Antibiotic Abuse) in the Physician Leadership Programme category. The award was presented at an event at Ho Chi Minh City, Vietnam.
- Fortis Hospital, Mohali was feted with the coveted Asia Pacific Hand Hygiene Award for 2016. Dr Anita Sharma, Head - Infection Control Committee, received the honour on behalf of Fortis Mohali at a ceremony in Bangkok.
- La Femme, New Delhi was ranked No. 2 in North India, 5th in the country in All India Critical Care Hospital Ranking Survey 2017.
- Fortis Escorts Hospital, Jaipur, became the first hospital in Rajasthan to receive the prestigious NABH Nursing Excellence accreditation, a testimony of the high nursing standard, unmatched expertise and relentless commitment towards patient welfare.
- Dr Ashok Seth, Chairman - Fortis Escorts Heart Institute, New Delhi was conferred with the prestigious 'Life Time Achievement Award in Interventional Cardiology' by the Chien Foundation, Singapore at the premier annual meeting of the Asian Pacific Interventional Cardiology – AsiaPCR SingLIVE 2017.
- Prof Dr Upendra Kaul, Dean and Executive Director, Clinical Research, Fortis Healthcare was appointed as the Co-Chairman of the "Expert Group for CV Diseases", under the Grant-in-Aid (GIA) scheme of Inter-Sectoral Convergence & Coordination for Promotion and Guidance on Health Research, by the Ministry of Health and Family Welfare, Government of India.



- Dr Vivek Jawali, Chairman - Cardiac Sciences, Fortis Hospitals, Bengaluru was selected as a member of Medical Council of India's special five-member committee formed to draw up an action plan to stimulate the growth of medical specialities and super specialities in India.

### **About Fortis Healthcare Limited**

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 45 healthcare facilities (including projects under development), approximately 10,000 potential beds and over 356 diagnostic centres.

#### **DISCLAIMER**

*This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.*

---

**For further details please contact:**

**Ajey Maharaj**  
**Fortis Healthcare Ltd**  
**9871798573**

**Anurag Kalra / Gaurav Chugh**  
**Fortis Healthcare Ltd**  
**9810109253 / 9958588900**